Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
PMID: 33423216 [PubMed - as supplied by publisher] (Source: Journal of Autism and Developmental Disorders)
Source: Journal of Autism and Developmental Disorders - January 9, 2021 Category: Psychiatry Authors: Crutel V, Lambert E, Penelaud PF, Albarrán Severo C, Fuentes J, Rosier A, Hervás A, Marret S, Oliveira G, Parellada M, Kyaga S, Gouttefangeas S, Bertrand M, Ravel D, Falissard B Tags: J Autism Dev Disord Source Type: research
High glucose-induced effects on Na+-K+-Cl- cotransport and Na+/H+ exchange of blood-brain barrier endothelial cells: involvement of SGK1, PKC βII and SPAK/OSR1.
High glucose-induced effects on Na+-K+-Cl- cotransport and Na+/H+ exchange of blood-brain barrier endothelial cells: involvement of SGK1, PKCβII and SPAK/OSR1.
Am J Physiol Cell Physiol. 2021 Jan 06;:
Authors: Klug NR, Chechneva OV, Hung BY, O'Donnell ME
Abstract
Hyperglycemia exacerbates edema formation and worsens neurological outcome in ischemic stroke. Edema formation in the early hours of stroke involves transport of ions and water across an intact blood-brain barrier (BBB), and swelling of astrocytes. We showed previously that high glucose (HG) exposures of 24 hours to 7 da...
Source: Am J Physiol Cell Ph... - January 6, 2021 Category: Cytology Authors: Klug NR, Chechneva OV, Hung BY, O'Donnell ME Tags: Am J Physiol Cell Physiol Source Type: research
Effects of α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator on BDNF, NKCC1 and KCC2 Expression in the Hippocampus following Lipopolysaccharide-induced Allodynia and Hyperalgesia in a Mouse Model of Inflammatory Pain.
CONCLUSION: These results suggest that antinociceptive effects of α7 nAChR PAM are associated with downregulation of hippocampal BDNF and p-NKCC1 and upregulation of KCC2 in a mouse model of inflammatory pain.
PMID: 33380307 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - December 29, 2020 Category: Drugs & Pharmacology Authors: Abbas M, Alzarea S, Papke RL, Rahman S Tags: CNS Neurol Disord Drug Targets Source Type: research
Treating Autism With Bumetanide: Are Large Multicentric and Monocentric Trials on Selected Populations Complementary?
Sprengers and colleagues conclude that Bumetanide does not attenuate autism spectrum disorder (ASD) despite a nominally significant treatment effect in repetitive behaviors (RBS) which is a core-symptom of ASD but was defined as a secondary measure in this trial.1 Four earlier studies performed by three independent institutes, including two that are not referred to2,3 by Sprengers and colleagues, tested a total of 169 children -vs 122 placebo- have shown a significant amelioration of ASD symptomatology. (Source: Journal of the American Academy of Child and Adolescent Psychiatry)
Source: Journal of the American Academy of Child and Adolescent Psychiatry - December 29, 2020 Category: Psychiatry Authors: Eric Lemonnier, Hamed Rabiei, David Makowski, Nouchine Hadjikhani, Yehezkel Ben-Ari Tags: Letter to the Editor Source Type: research
Overexpression of chloride importer NKCC1 contributes to the sensory-affective and sociability phenotype of rats following neonatal maternal separation.
CONCLUSIONS: This work suggests that an impaired chloride homeostasis, linked to oxytocin signaling dysfunction and to neuro-inflammatory processes, could contribute to the sensori-affective phenotype following NMS.
PMID: 33316378 [PubMed - as supplied by publisher] (Source: Brain, Behavior, and Immunity)
Source: Brain, Behavior, and Immunity - December 11, 2020 Category: Neurology Authors: Gazzo G, Melchior M, Caussaint A, Gieré C, Lelièvre V, Poisbeau P Tags: Brain Behav Immun Source Type: research
The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain
Publication date: Available online 2 December 2020Source: Epilepsy & BehaviorAuthor(s): Philip Hampel, Kerstin Römermann, Martina Gramer, Wolfgang Löscher (Source: Epilepsy and Behavior)
Source: Epilepsy and Behavior - December 4, 2020 Category: Neurology Source Type: research
The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.
Abstract
Because of its potent inhibitory effect on the Na+-K+-2Cl- symporter isotype 1 (NKCC1) in brain neurons, bumetanide has been tested with varying results for treatment of seizures that potentially evolve as a consequence of abnormal NKCC1 activity. However, because of its physicochemical properties, bumetanide only poorly penetrates into the brain. We previously demonstrated that NKCC1 can be also inhibited by azosemide and torasemide, which lack the carboxyl group of bumetanide and thus should be better brain-permeable. Here we studied the brain distribution kinetics of azosemide and torasemide in...
Source: Epilepsy and Behaviour - December 2, 2020 Category: Neurology Authors: Hampel P, Römermann K, Gramer M, Löscher W Tags: Epilepsy Behav Source Type: research
Editorial: Targeting the Core Symptoms of Autism Spectrum Disorder With Mechanism-based Medications
Medications can help manage behavioral problems associated with autism spectrum disorder (ASD), but no pharmacological treatment has proved effective for the core symptoms of the disorder. This issue reports the primary results of the randomized clinical trial Bumetanide in Autism Medication and Biomarker (BAMBI), which tested the efficacy of bumetanide, a loop diuretic acting as a selective antagonist of the chloride importer NKCC1, for the core symptoms of ASD in 92 children aged 7-15 years.1 The study by Sprengers et al. (Source: Journal of the American Academy of Child and Adolescent Psychiatry)
Source: Journal of the American Academy of Child and Adolescent Psychiatry - November 16, 2020 Category: Psychiatry Authors: Benedetto Vitiello Tags: Editorial Source Type: research
Editorial: Targeting the Core Symptoms of Autism Spectrum Disorder With Mechanism-based
Medications can help manage behavioral problems associated with autism spectrum disorder (ASD), but no pharmacological treatment has proved effective for the core symptoms of the disorder. This issue reports the primary results of the randomized clinical trial Bumetanide in Autism Medication and Biomarker (BAMBI), which tested the efficacy of bumetanide, a loop diuretic acting as a selective antagonist of the chloride importer NKCC1, for the core symptoms of ASD in 92 children aged 7-15 years.1 The study by Sprengers et al. (Source: Journal of the American Academy of Child and Adolescent Psychiatry)
Source: Journal of the American Academy of Child and Adolescent Psychiatry - November 16, 2020 Category: Psychiatry Authors: Benedetto Vitiello Tags: Editorial Source Type: research
DRESS syndrome following furosemide administration: An unusual association.
CONCLUSION: We add to the literature another case of furosemide-induced DRESS with the particularity of cross reactivity with bumetanide.
PMID: 33203615 [PubMed - as supplied by publisher] (Source: Nephrologie and Therapeutique)
Source: Nephrologie and Therapeutique - November 14, 2020 Category: Urology & Nephrology Authors: Ben Fadhel N, Ben Romdhane H, Chaabane A, Belhadj Ali H, Boughattas NA, Aouam K, Ben Fredj N Tags: Nephrol Ther Source Type: research
Preliminary study of analgesic effect of bumetanide on neuropathic pain in patients with spinal cord injury
Publication date: November 2020Source: Journal of Clinical Neuroscience, Volume 81Author(s): Leila Zarepour, Zeinab Gharaylou, Mahmoudreza Hadjighassem, Lida Shafaghi, Hossein Majedi, Ebrahim Behzad, Saereh Hosseindoost, Fatemeh Ramezani, Farinaz Nasirinezhad (Source: Journal of Clinical Neuroscience)
Source: Journal of Clinical Neuroscience - November 6, 2020 Category: Neuroscience Source Type: research
Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
We describe the design of two Phase III studies evaluating the efficacy/safety of bumetanide oral liquid formulation in ASD. These are international, multicenter, randomized, double-blind, placebo-controlled studies in children and adolescents with ASD aged 7 to 17 years (n = 200; study 1), or younger children with ASD aged 2 to 6 years (n = 200; study 2). The primary endpoint of each is change in Childhood Autism Rating Scale 2 total raw score after 6 months. These studies could contribute to the first pharmacological treatment to improve social reciprocity and limit repetitive and rigid behaviors in children a...
Source: Journal of Autism and Developmental Disorders - November 5, 2020 Category: Psychiatry Authors: Crutel V, Lambert E, Penelaud PF, Albarrán Severo C, Fuentes J, Rosier A, Hervás A, Marret S, Oliveira G, Parellada M, Kyaga S, Gouttefangeas S, Bertrand M, Ravel D, Falissard B Tags: J Autism Dev Disord Source Type: research
Preventing neuronal edema increases network excitability after traumatic brain injury
Edema is an important target for clinical intervention after traumatic brain injury (TBI). We used in vivo cellular resolution imaging and electrophysiological recording to examine the ionic mechanisms underlying neuronal edema and their effects on neuronal and network excitability after controlled cortical impact (CCI) in mice. Unexpectedly, we found that neuronal edema 48 hours after CCI was associated with reduced cellular and network excitability, concurrent with an increase in the expression ratio of the cation-chloride cotransporters (CCCs) NKCC1 and KCC2. Treatment with the CCC blocker bumetanide prevented neuronal ...
Source: Journal of Clinical Investigation - October 13, 2020 Category: Biomedical Science Authors: Punam A. Sawant-Pokam, Tyler J. Vail, Cameron S. Metcalf, Jamie L. Maguire, Thomas O. McKean, Nick O. McKean, K.C. Brennan Source Type: research
Intracardiac Thrombus in Sinus Rhythm: A Case of Missed Cardiac Amyloidosis
We describe a case of a 59 year-old female who presented to the hospital with dyspnea on exertion, orthopnea, pedal edema, and weight gain. She had a one year history of heart failure with preserved ejection fraction, treated with metoprolol, bumetanide, and metolazone, and three month history of AL amyloidosis, treated with Bortezomib and Dexamethasone. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - September 30, 2020 Category: Cardiology Authors: Jennifer DeSalvo, Benjamin Buck, Ajay Vallakati Tags: 314 Source Type: research
Treatment Updates for Neuromuscular Channelopathies
This article aims to review the current and upcoming treatment options of primary muscle channelopathies including the non-dystrophic myotonias and periodic paralyses.Recent findingsThe efficacy of mexiletine in the treatment of myotonia is now supported by two randomised placebo-controlled trials, one of which utilised a novel aggregated n-of-1 design. This has resulted in licencing of the drug via orphan drug status. There is also good evidence that mexiletine is well tolerated and safe in this patient group without the need for intensive monitoring. A range of alternative antimyotonic treatment options include lamotrigi...
Source: Current Treatment Options in Neurology - August 21, 2020 Category: Neurology Source Type: research
